Inotiv Expands Protein/Peptide Bioanalytical Capabilities With This Deal

  • Contract research organization Inotiv Inc NOTV acquired Nashville, Tennessee-based Protypia Inc for $11 million.
  • Inotiv specializes in nonclinical and analytical drug discovery, development services, research models, and related products and services.
  • Protypia is a protein/peptide bioanalytical company offering high-quality, targeted tissue-based protein and peptide mass spectrometry.
  • Deal consideration consists of approximately $9.5 million in cash, Inotiv common shares of approximately $0.9 million, and $0.6 million in unsecured subordinated promissory notes.
  • The company expects to retain all existing Protypia employees and maintain operations in Nashville.
  • "This highly-specialized technology and know-how significantly enhances our ability to support clients in developing safe and effective medicines, particularly in the areas of immuno-oncology and cell and gene therapy. The ability to precisely quantify protein levels in tissues, including paraffin-embedded tissues, opens exciting new avenues for scientists to explore as they investigate disease pathways," said John Sagartz, Inotiv's Chief Strategy Officer.
  • Price Action: NOTV shares closed 2.53% higher at $10.94 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: M&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!